ES2139132T3 - Composiciones farmaceuticas activas en la terapia de desordenes del sueño. - Google Patents

Composiciones farmaceuticas activas en la terapia de desordenes del sueño.

Info

Publication number
ES2139132T3
ES2139132T3 ES95118386T ES95118386T ES2139132T3 ES 2139132 T3 ES2139132 T3 ES 2139132T3 ES 95118386 T ES95118386 T ES 95118386T ES 95118386 T ES95118386 T ES 95118386T ES 2139132 T3 ES2139132 T3 ES 2139132T3
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
sleep disorders
compositions active
therapy
disorders therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95118386T
Other languages
English (en)
Inventor
Gabriele Biella
Franco Fraschini
Bojidar Stanvok
Strambi Luigi Ferini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
I F L O ISTITUTO FARMACOLOGICO
Original Assignee
I F L O ISTITUTO FARMACOLOGICO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I F L O ISTITUTO FARMACOLOGICO filed Critical I F L O ISTITUTO FARMACOLOGICO
Application granted granted Critical
Publication of ES2139132T3 publication Critical patent/ES2139132T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A NUEVAS COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN CANTIDADES EFECTIVAS TERAPEUTICAMENTE DE 2-BROMOMELATONINA PARA UTILIZACION EN LA TERAPIA DE LOS TRASTORNOS DEL SUEÑO Y EN LA MEDICACION PREANESTESICA.
ES95118386T 1991-05-13 1992-05-11 Composiciones farmaceuticas activas en la terapia de desordenes del sueño. Expired - Lifetime ES2139132T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
EP92107865A EP0513702B1 (en) 1991-05-13 1992-05-11 Melatonin derivaties for use in the therapy of sleep disorders and in pre-anaesthetic medication

Publications (1)

Publication Number Publication Date
ES2139132T3 true ES2139132T3 (es) 2000-02-01

Family

ID=11359886

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92107865T Expired - Lifetime ES2093735T3 (es) 1991-05-13 1992-05-11 Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
ES95118386T Expired - Lifetime ES2139132T3 (es) 1991-05-13 1992-05-11 Composiciones farmaceuticas activas en la terapia de desordenes del sueño.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES92107865T Expired - Lifetime ES2093735T3 (es) 1991-05-13 1992-05-11 Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.

Country Status (9)

Country Link
US (1) US5430029A (es)
EP (2) EP0513702B1 (es)
JP (1) JPH05155769A (es)
AT (2) ATE184792T1 (es)
DE (2) DE69213814T2 (es)
DK (2) DK0513702T3 (es)
ES (2) ES2093735T3 (es)
GR (2) GR3022060T3 (es)
IT (1) IT1251544B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0483077B1 (en) * 1990-09-28 1995-12-06 I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IT1262912B (it) * 1992-12-30 1996-07-22 Impiego della melatonina nella terapia della sclerosi sistemica, della sarcoidosi ed altro
AU726758B2 (en) * 1993-11-18 2000-11-23 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5763471A (en) * 1994-04-07 1998-06-09 Cemaf Melatoninergic agonist spiro indolepyrrolidine! derivatives, process for their preparation and their use as medicinal products
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
CN1083263C (zh) * 1995-02-01 2002-04-24 纽里姆药品(1991)有限公司 褪黑激素在治疗药物成瘾之患者中的应用
WO1999063977A2 (en) * 1998-06-09 1999-12-16 Takeda Chemical Industries, Ltd. Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone, triazolam and brotizolam for treating or preventing sleep disorders
FR2787447B1 (fr) * 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CA2360124A1 (en) * 1999-02-05 2000-08-10 The Victoria University Of Manchester Regulation of anaesthesia
US6638966B2 (en) 2000-09-19 2003-10-28 University Of Iowa Research Foundation Use of melatonin analogues for induction of general anesthesia
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
DK1691811T3 (da) * 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
DK1742624T3 (da) 2004-02-18 2010-03-08 Sepracor Inc Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet
US8053462B2 (en) 2004-03-08 2011-11-08 Masanori Somei Indole derivative and application thereof
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20090105333A1 (en) * 2006-05-22 2009-04-23 Gunther Birznieks Melatonin agonist treatment
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
EP4502609A3 (en) 2012-01-26 2025-04-09 Vanda Pharmaceuticals Inc. Determining a circadian rhythm
ES2805376T3 (es) 2012-12-18 2021-02-11 Vanda Pharmaceuticals Inc Tasimelteón para el tratamiento de trastornos del ritmo circadiano
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
EP4478887A4 (en) * 2022-02-16 2026-01-28 La Pharma Tech Inc NEW PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT FOR INSOMNIA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
WO1989001472A1 (en) * 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues

Also Published As

Publication number Publication date
ES2093735T3 (es) 1997-01-01
US5430029A (en) 1995-07-04
EP0513702A2 (en) 1992-11-19
IT1251544B (it) 1995-05-17
DK0713701T3 (da) 2000-04-03
DE69213814T2 (de) 1997-04-03
ITMI911299A1 (it) 1992-11-13
EP0713701B1 (en) 1999-09-22
DE69213814D1 (de) 1996-10-24
JPH05155769A (ja) 1993-06-22
DK0513702T3 (da) 1996-12-30
ITMI911299A0 (it) 1991-05-13
GR3022060T3 (en) 1997-03-31
DE69230046D1 (de) 1999-10-28
DE69230046T2 (de) 2000-05-31
EP0513702B1 (en) 1996-09-18
GR3032207T3 (en) 2000-04-27
ATE142877T1 (de) 1996-10-15
ATE184792T1 (de) 1999-10-15
EP0513702A3 (en) 1992-11-25
EP0713701A1 (en) 1996-05-29

Similar Documents

Publication Publication Date Title
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
MX171191B (es) Composiciones farmaceuticas de glipizida
DE3382641D1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
ES2188586T3 (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento para la profilaxis y terapia de enfermedades inflamatorias intestinales y de la piel, asi como purpura.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
ES2037086T3 (es) Procedimiento para preparar formulaciones farmaceuticas.
ES2061989T3 (es) Uso de esteres alquilicos del acido piroglutamico para la fabricacion de un medicamento para el tratamiento de la ictiosis.
ES2130152T3 (es) Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
ES2062100T3 (es) Empleo de acetil l-carnitina en el tratamiento terapeutico de cataratas y composiciones farmaceuticas utiles en este tratamiento.
ES2158597T3 (es) Compuestos bioaromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
PT97300A (pt) Processo para a preparacao de esteres de acidos 1,4-di-hidropiridinocarboxilicos n-alquilados e de medicamentos que os contem
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
SE8002715L (sv) Injicerbara lekemedel med inflammationshemmande verkan samt sett for framstellning derav
DE69928806D1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 713701

Country of ref document: ES